Others.

Last updated: 2021 Sep 5
Total hit(s): 7
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
15 DEGs were identified which were identified as potential therapeutic targets against COVID-19, which were related to 46 FDA approved or clinical trial drugs. 3 of them (ALP,CXCL8, IL6) were already targeted in patients infected with SARS-CoV-2 with an additional 35 drugs that target these proteins but have not been tested against the disease. 4 novel potential targets ( CCL20, CSF3, CXCL10) were identified with 6 existing drugs that could be repurposed. 8 further targets ( CXCL6, IFI44, IFI44L, RSAD2, S100A8, SPRR2A, SYNE1, XAF1) associated with the disease were identified but drugs targeting these are under clinical trial or is approved for another indication.
✍
 		Pre-print (medRXiv)
Title Drug Repurposing of potential drug targets for treatment of COVID-19
Impact factor
N/A
Date of Entry 2021 Sep 5

Cathepsin L (CTSL) levels increased in SARS-CoV-2 infected mice's liver.Cathepsin L inhibitor, Amantadine reduced the levels of CTSL. CTSL levels increased in the lungs of infected mice, on inhibitor treatment, no statistically significant result was observed.
✍
 		33774649
(Signal Transduct Target Ther)
PMID
33774649
Date of Publishing: 2021 Mar 27
Title Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) nameZhao MM, Yang WL et al.
Journal Signal Transduct Target Ther
Impact factor
- n/a -
Citation count: 73
Date of Entry 2021 Aug 23

Cathepsin L (CTSL) levels increased in SARS-CoV-2 infected mice's liver.Cathepsin L inhibitor, E64d reduced the levels of CTSL. CTSL levels increased in the lungs of mice infected with the pseudovirus, on inhibitor treatment no statistically significant result was observed.
✍
 		33774649
(Signal Transduct Target Ther)
PMID
33774649
Date of Publishing: 2021 Mar 27
Title Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Author(s) nameZhao MM, Yang WL et al.
Journal Signal Transduct Target Ther
Impact factor
- n/a -
Citation count: 73
Date of Entry 2021 Aug 23

Comparative In silico analyses of SARS-CoV-2 genomic features (codon, codon pair, dinucleotide usage, and RNA structure around the frameshift region) was performed to find out the best potential target gene for codon pair deoptimization. Genes N and S are suggested as best targets, because of high codon pair bias (CPB) compared to that of other viral genes. 5,064 complete SARS-CoV-2 genomes were analyzed The codon and codon pair usage was calculated for all the genes coded by SARS-CoV-2. Relative synonymous codon usage (RSCU) and codon pair score (CPS) are the metrics that describe the codon and codon pair usage bias, respectively. The codon pair bias (CPB) is the average CPS across a gene.
✍
 		32973171
(Sci Rep)
PMID
32973171
Date of Publishing: 2020 Sep 24
Title Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
Author(s) nameKames J, Holcomb DD et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 22

Efficacy of remdesivir in a rhesus macaque infected with SARS-CoV-2 shows reduced pulmonary infiltrates and virus titres.. This study shows that remdesivir treatment should be considered as early as clinically possible to prevent progression to pneumonia in COVID-19 patients.
✍
 		32516797
(Nature)
PMID
32516797
Date of Publishing: 2020 Sep
Title Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Author(s) nameWilliamson BN, Feldmann F et al.
Journal Nature
Impact factor
24.36
Citation count: 325

Compound 13a has IC50 of 2.39 ± 0.63 µ;M against SARS-CoV-2 main protease. 13a was cleared at a rapid rate from plasma, at 24 hours it was found at 135 ng/g tissue in the lung and at 52.7 ng/ml in bronchio-alveolar lavage fluid (BALF), showing it was distributed into the tissues, thus very useful anti-coronavirus drug.
✍
 		32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 1159

Compound 13b inhibits the purified recombinant SARS-CoV-2 Mpro with IC50 = 0.67 ± 0.18 μ;M. In human Calu-3 cells infected with SARS-CoV-2 it has an EC50 of 4 to 5 μ;M. After 24 hours, 13b was found at 33 ng/g in lung tissue. Inhalation was tolerated well and mice did not show any adverse effects, which suggests that direct administration of the compound to the lungs would be possible.
✍
 		32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 1159